The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with one or more pre-cachexia and/or cachexia-associated RAGE ligands or markers.
本发明提供了具有治疗作用的工程化蛋白质/肽组合物,这些组合物由 RAGE
抗体、T 细胞受体等组成,可直接靶向 RAGE 受体(包括其可溶形式)和/或通过与一种或多种恶性肿瘤前和/或恶性肿瘤相关的 RAGE
配体或标记物的差异竞争靶向 RAGE 受体。